Safety of COVID‐19 vaccine challenge in patients with immediate adverse reactions to prior doses: A multi‐centre cohort study.

Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose. Atopy and hospitalization were not associated with an increased risk of positive challenge, suggesting those at risk of positive challenge lack classical allergy phenotypes. Keywords: allergy; challenge; COVID-19; SARS-CoV-2; vaccine EN allergy challenge COVID-19 SARS-CoV-2 vaccine 293 296 4 12/30/22 20230101 NES 230101 Severe immediate adverse events following immunization (AEFI) with COVID-19 vaccines have been reported in up to 2.5 per 10,000 vaccinations.[1] Differentiating allergic reactions from immunization stress-related responses (ISRR)[2] at the point of vaccination can be difficult, presenting an added burden to allergy clinics. [Extracted from the article]